Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines reports developments for a central nervous system precision neuroscience biopharmaceutical company focused on therapies for disorders involving neuronal excitation-inhibition imbalance. Its recurring updates cover the Cerebrum small molecule platform, the Solidus antisense oligonucleotide platform, and product candidates across movement disorders and epilepsy, including ulixacaltamide, relutrigine, vormatrigine and elsunersen.
Company news commonly addresses FDA review activity, clinical trial data, scientific presentations, operating and financial results, commercial-readiness updates, equity inducement grants under Nasdaq rules and governance matters. Disease areas highlighted in its disclosures include essential tremor and developmental and epileptic encephalopathies associated with SCN2A and SCN8A.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Praxis Precision Medicines (NASDAQ: PRAX) announced its presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting, scheduled from April 22-27 in Boston. The company aims to discuss significant advances in its clinical programs focused on central nervous system disorders. Noteworthy highlights include the release of topline results from the ulixacaltamide Essential1 Phase 2 study in essential tremor and upcoming patient doses for the PRAX-222 EMBRAVE and PRAX-562 EMBOLD studies. The presentations will cover key topics such as the challenges of SCN2A and SCN8A-related disorders. These updates underscore Praxis' commitment to developing innovative therapies for CNS conditions.
Praxis Precision Medicines (NASDAQ: PRAX) has scheduled an end-of-phase 2 meeting with the FDA for ulixacaltamide, aimed at treating Essential Tremor (ET), in June 2023. The company will also present key findings from its Essential1 trial at various medical conferences, including the 75th Annual AAN on April 23, 2023, and the World Congress on Parkinson’s Disease on May 15, 2023. Ulixacaltamide is a selective T-type calcium channel blocker designed to mitigate tremor activity, a common neurological disorder affecting roughly seven million people in the U.S. The current pharmacotherapy options are limited, underscoring the need for effective treatments, which may position ulixacaltamide favorably in the market.
Praxis Precision Medicines (NASDAQ: PRAX) has announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 p.m. ET. The presentation will be accessible via a live webcast on the company's website, with a replay available for 90 days post-event.
Praxis focuses on developing therapies for central nervous system (CNS) disorders that stem from neuronal excitation-inhibition imbalances. The company utilizes its proprietary platforms, Cerebrum™ and Solidus™, to leverage genetic insights for creating therapies for rare and prevalent neurological conditions. With a diverse portfolio, Praxis has multiple clinical-stage product candidates targeting movement disorders and epilepsy.
BOSTON, March 3, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (NASDAQ: PRAX), focused on CNS disorders, will participate in key investor conferences. They will take part in the 43rd Annual TD Cowen Health Care Conference on March 6, 2023, featuring a panel on orphan epilepsies at 12:50 p.m. ET. Additionally, Praxis will join the Needham Neuroscience Forum for a fireside chat on March 15, 2023, at 2:00 p.m. ET. Both events will be accessible via live webcast on their website, with replays available for 30 days post-event. Praxis is advancing therapies for neurological disorders using its proprietary platforms.
Praxis Precision Medicines (NASDAQ: PRAX) announced topline results from the Phase 2b Essential1 study of ulixacaltamide for treating essential tremor. The primary endpoint of improvement in modified Activities of Daily Living (mADL) did not reach statistical significance (p=0.126), but a secondary endpoint, the TETRAS-ADL, showed nominal significance (p=0.026). The drug was well tolerated, with no new safety findings reported. Praxis plans to engage with the FDA for an end-of-Phase 2 meeting and initiate a Phase 3 study in 2H23, as the unmet need for effective therapies for essential tremor persists.
Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update and financial results for Q4 and full year 2022, highlighting a transformative 2023 ahead with topline results from the ulixacaltamide Essential1 study expected in 1Q23. The company reported cash and investments of $100.5 million as of December 31, 2022, which funds operations into 1Q24. R&D expenses increased to $155 million in 2022, with net losses of $214 million.
Key milestones for 2023 include results from their clinical programs, including PRAX-562 and PRAX-628. A strategic collaboration with UCB could yield up to $100 million in milestone payments for the KCNT1 program.